...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Potential Scope of Indications for Apabetalone (selective BRD/BD inhibition)

Can one imagine the possibility of Apabetalone  taking the same steps that Humira took with Adalimumab way back that let  Abbie buy Humira  and sell  $200 billion worth of Adalimumab for many different indications over the years . This would be field day for any Pharma. Dm mentioned at the Zenith AGM that he had spoken to the former CEO of Humira , just wondering when and if this could happen to RVX , I think another management team needs to come for this to happen 

Share
New Message
Please login to post a reply